Edition:
United States

Recipharm AB (publ) (RECIb.ST)

RECIb.ST on Stockholm Stock Exchange

88.75SEK
14 Dec 2017
Change (% chg)

-1.00kr (-1.11%)
Prev Close
89.75kr
Open
90.00kr
Day's High
90.75kr
Day's Low
88.00kr
Volume
31,843
Avg. Vol
160,458
52-wk High
131.00kr
52-wk Low
84.00kr

Latest Key Developments (Source: Significant Developments)

Recipharm Q3 EBITDA down at SEK ‍103​ mln
Thursday, 9 Nov 2017 01:45am EST 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) ::Q3 EBITDA SEK ‍103​ MILLION VERSUS SEK 144 MILLION YEAR AGO.Q3 NET SALES SEK ‍1.20​ BILLION VERSUS SEK 1.14 BILLION YEAR AGO.  Full Article

Recipharm Q3 EBITDA down at SEK ‍103​ mln
Thursday, 9 Nov 2017 01:45am EST 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) :Q3 NET SALES SEK ‍1.20 BILLION VERSUS SEK 1.14 BILLION YEAR AGO.Q3 EBITDA SEK ‍103​ MILLION VERSUS SEK 144 MILLION YEAR AGO.  Full Article

Recipharm to end operations in two facilities in Sweden
Thursday, 9 Nov 2017 01:44am EST 

Nov 9 (Reuters) - RECIPHARM AB (PUBL) ::RECIPHARM TO END OPERATIONS IN TWO FACILITIES IN SWEDEN.‍TO START A PROCESS WITH INTENTION OF DISCONTINUING ACTIVITIES BOTH IN STOCKHOLM AND HÖGANÄS.​.‍WILL EXPLORE OPPORTUNITY TO CLOSE FACILITIES DURING SECOND HALF OF 2019​.SAYS ‍WILL EVALUATE DIFFERENT OPTIONS FOR FACILITY SUCH AS DIVESTMENT OF MANUFACTURING SITE​.‍FINAL DECISION REGARDING DISCONTINUED MANUFACTURING OPERATIONS IN STOCKHOLM AND HÖGANÄS TO BE MADE BEFORE END-2017.‍CLOSURE AFFECTS APPROXIMATELY 225 OF SWEDISH EMPLOYEES​.‍WILL EXPLORE OPPORTUNITY TO CLOSE FACILITIES IN GREATER STOCKHOLM AREA DURING SECOND HALF OF 2019​.‍ESTIMATED NON-RECURRING COSTS ASSOCIATED WITH DECISION TO DISCONTINUE OPERATIONS ARE EXPECTED TO BE CHARGED TO Q4​.‍ESTIMATED NON-RECURRING COSTS ASSOCIATED WITH DECISION TO BE CHARGED TO Q4 RESULTS​.  Full Article

Recipharm starts cooperation with Roche
Wednesday, 20 Sep 2017 01:45am EDT 

Sept 20 (Reuters) - RECIPHARM AB (PUBL) :RECIPHARM SIGNS LONG-TERM MANUFACTURING AGREEMENT WITH MAJOR NEW CUSTOMER AND ACQUIRES FACILITY IN SPAIN.‍ENTERED INTO COLLABORATION WITH ROCHE​.‍WILL ALSO ACQUIRE A MANUFACTURING FACILITY CURRENTLY EMPLOYING APPROXIMATELY 200 PEOPLE LOCATED IN LEGANÉS, SPAIN, FROM ROCHE​.‍LONG-TERM AGREEMENT WILL ADD ANNUAL SALES OF ABOUT EUR 35 MILLION CORRESPONDING TO MORE THAN 6% OF CURRENT GROUP SALES​.‍CLOSING OF TRANSACTION AND COMMENCEMENT OF SUPPLY UNDER AGREEMENT IS ANTICIPATED BY YEAR END 2017.​.  Full Article

Recipharm, Kancera cooperate to manufacture clinical trial supply
Thursday, 14 Sep 2017 02:30am EDT 

Sept 14 (Reuters) - RECIPHARM AB (PUBL) :RECIPHARM AND KANCERA <<>> COLLABORATE TO MANUFACTURE CLINICAL TRIAL SUPPLY.‍AS PART OF COLLABORATION, CO TO DEVELOP PREPARATION THAT IS REQUIRED FOR RELEASE OF KAND567 FROM CAPSULES AND MANUFACTURING PHARMACEUTICAL PRODUCT​.  Full Article

Recipharm Q2 EBITDA SEK 242 million
Tuesday, 25 Jul 2017 01:45am EDT 

July 25 (Reuters) - RECIPHARM AB (PUBL) :Q2 NET SALES SEK ‍1.40 BILLION VERSUS SEK 1.24 BILLION YEAR AGO​.Q2 EBITDA SEK 242 MILLION VERSUS SEK 240 MILLION YEAR AGO.‍I'M CONFIDENT THAT OUR LONG-TERM OBJECTIVES WILL BE ACHIEVED - CEO​."‍CERTAIN DELAYS ARE CAUSING SOME UNCERTAINTY AND TOGETHER WITH NON-RECURRING COSTS IN Q1 THIS MAY MAKE IT A BIT OF A CHALLENGE TO FULLY REACH MARGIN TARGET FOR 2017."​.RECIPHARM -CERTAIN DELAYS ARE CAUSING UNCERTAINTY AND NON-RECURRING COSTS IN Q1 MAY MAKE IT CHALLENGE TO REACH 2017 MARGIN TARGET​.  Full Article

Recipharm EBITDA margin falls to 12 pct in Q1
Thursday, 27 Apr 2017 01:45am EDT 

April 27 (Reuters) - Recipharm AB (Publ) :Q1 net sales amounted to SEK 1,328 million (973), an increase of 37 pct.Q1 EBITDA SEK 159 million (136) corresponding to an EBITDA margin of 12 pct (14).Says despite an exceptionally weak start of year profit wise, underlying business is developing according to our plans and we maintain our sales growth and ebitda-margin objectives along with our leverage targets.Says confident that these objectives will be achieved.  Full Article

Recipharm appoints Henrik Stenqvist as new CFO
Tuesday, 11 Apr 2017 01:45am EDT 

Recipharm :Recipharm appoints Henrik Stenqvist as new Chief Financial Officer.  Full Article

Recipharm Q4 EBITDA 229 mln SEK
Thursday, 23 Feb 2017 01:45am EST 

Recipharm AB : Q4 net sales amounted to sek 1 333 million (863), an increase of 54% . Recipharm ab (publ) says proposed share dividend is sek [1.50] (1.50) per share . Q4 ebitda increased by 108% and amounted to sek 229 million (110) .Recipharm ab (publ) says we are well on track to reach our long-term financial targets and overall objectives.  Full Article

Recipharm places SEK 1,000 mln convertible bonds
Thursday, 29 Sep 2016 12:00pm EDT 

Recipharm Ab (Publ) : Says places SEK 1,000 million senior unsecured convertible bonds .Says the bonds will carry a coupon of 2.75 pct per annum, and have a conversion price set at SEK 181.955.  Full Article

BRIEF-Recipharm commences new supply contract

* RECIPHARM COMMENCES NEW SUPPLY CONTRACT AND COMPLETES PURCHASE OF FACILITY IN SPAIN Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)